EA021584B1 - Ингибитор рецептора фактора роста фибробластов-3 (fgfr-3) и его применение - Google Patents

Ингибитор рецептора фактора роста фибробластов-3 (fgfr-3) и его применение Download PDF

Info

Publication number
EA021584B1
EA021584B1 EA201170590A EA201170590A EA021584B1 EA 021584 B1 EA021584 B1 EA 021584B1 EA 201170590 A EA201170590 A EA 201170590A EA 201170590 A EA201170590 A EA 201170590A EA 021584 B1 EA021584 B1 EA 021584B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
popk
zeg
cells
rgo
Prior art date
Application number
EA201170590A
Other languages
English (en)
Russian (ru)
Other versions
EA201170590A1 (ru
Inventor
Хайцзюнь Сунь
Лин Лю
Original Assignee
Имклоун Элэлси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Имклоун Элэлси filed Critical Имклоун Элэлси
Publication of EA201170590A1 publication Critical patent/EA201170590A1/ru
Publication of EA021584B1 publication Critical patent/EA021584B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201170590A 2008-10-20 2009-10-15 Ингибитор рецептора фактора роста фибробластов-3 (fgfr-3) и его применение EA021584B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19685508P 2008-10-20 2008-10-20
PCT/US2009/060840 WO2010048026A2 (en) 2008-10-20 2009-10-15 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Publications (2)

Publication Number Publication Date
EA201170590A1 EA201170590A1 (ru) 2011-10-31
EA021584B1 true EA021584B1 (ru) 2015-07-30

Family

ID=42062445

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170590A EA021584B1 (ru) 2008-10-20 2009-10-15 Ингибитор рецептора фактора роста фибробластов-3 (fgfr-3) и его применение

Country Status (17)

Country Link
US (3) US8043618B2 (enExample)
EP (1) EP2342232A2 (enExample)
JP (1) JP5577345B2 (enExample)
KR (1) KR101370798B1 (enExample)
CN (2) CN103524620A (enExample)
AR (1) AR073770A1 (enExample)
AU (1) AU2009307841B2 (enExample)
BR (1) BRPI0919832A8 (enExample)
CA (1) CA2741127C (enExample)
EA (1) EA021584B1 (enExample)
IL (1) IL211807A0 (enExample)
MX (1) MX2011004317A (enExample)
NZ (1) NZ592369A (enExample)
TW (1) TWI381848B (enExample)
UA (1) UA101681C2 (enExample)
WO (1) WO2010048026A2 (enExample)
ZA (1) ZA201101938B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
ES2549769T3 (es) 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
US20150344855A1 (en) 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック， インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
MX373805B (es) 2014-03-25 2020-03-24 Regeneron Pharma Agonistas de receptor fgf21 y usos del mismo.
US20170101466A1 (en) * 2014-06-03 2017-04-13 Masahisa Handa Anti-blys antibodies
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
AU2015311725A1 (en) * 2014-09-05 2017-04-20 Hyperfine Research, Inc. Thermal management methods and apparatus
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
SG11201706727XA (en) * 2015-02-19 2017-09-28 Bioclin Therapeutics Inc Methods, compositions, and kits for treatment of cancer
WO2016139227A1 (en) 2015-03-03 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Fgfr3 antagonists
TW201711702A (zh) * 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
KR102432192B1 (ko) 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
TW201833140A (zh) * 2017-01-09 2018-09-16 美商莫瑞麥克製藥公司 抗fgfr抗體及使用方法
TW202229343A (zh) 2020-08-21 2022-08-01 美商健臻公司 Fgfr3抗體及使用方法
CN114015770B (zh) * 2021-12-30 2022-04-26 佛山市第三人民医院(佛山市精神卫生中心) 精神分裂全外周血rna标志物fgfr3及其应用
AU2023379457A1 (en) * 2022-11-14 2025-05-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
CN121002062A (zh) 2023-01-13 2025-11-21 再生元制药公司 Fgfr3结合分子及其使用方法
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102973A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2005066211A2 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
US20100003258A1 (en) * 2008-07-01 2010-01-07 Zhigang Weng Fibroblast growth factor receptor 3 (fgfr3) binding proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US7960518B2 (en) * 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
CA2663388C (en) * 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP2185719B1 (en) * 2007-08-02 2013-11-13 NovImmune SA Anti-rantes antibodies and methods of use thereof
TW201920257A (zh) * 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
AR073770A1 (es) * 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102973A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2005066211A2 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
US20100003258A1 (en) * 2008-07-01 2010-01-07 Zhigang Weng Fibroblast growth factor receptor 3 (fgfr3) binding proteins

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHELLAIAH A. ET AL.: "MAPPING LIGAND BINDING DOMAINS IN CHIMERIC FIBROBLAST GROWTH FACTOR RECEPTOR MOLECULES". JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.274.49.34785, vol. 274, no. 49, 3 December 1999 (1999-12-03), pages 34785-34794, XP002951247, ISSN: 0021-9258 the whole document *
DVORAK P. ET AL.: "Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia". LEUKEMIA (BASINGSTOKE), vol. 17, no. 12, December 2003 (2003-12), pages 2418-2425, XP007913082, ISSN: 0887-6924, The whole document, in particular the methods; line 1 - page 2420, column 2, line 2 *
KEEGAN K. ET AL.: "ISOLATION OF AN ADDITIONAL MEMBER OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FAMILY, FGFR-3" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD-DOI:10.1073/PNAS.88.4.1095, vol. 88, 1 February 1991 (1991-02-01), pages 1095-1099, XP002071229, ISSN: 0027-8424, the whole document *
MARTINEZ-TORRECUADRADA J. ET AL.: "Targeting the Extracellular Domain of Fibroblast Growth Factor Receptor 3 with Human Single-Chain Fv Antibodies Inhibits Bladder Carcinoma Cell Line Proliferation". CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US LNKD-DOI:10.1158/1078-0432.CCR-05-0282, vol. 11, no. 17, 1 September 2005 (2005-09-01), pages 6280-6290, XP003013913, ISSN: 1078-0432, cited in the application, the whole document *
RAUCHENBERGER R. ET AL.: "Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3". JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD-DOI:10.1074/JBC.M303164200, vol. 278, no. 40, 3 July 2003 (2003-07-03), pages 38194-38205, XP002404703, ISSN: 0021-9258, the whole document *
SCOTET EMMANUEL ET AL.: "The choice between alternative IHb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific". BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1264, no. 2, 1995, pages 238-242, XP009133572, ISSN: 0006-3002, the whole document *
SUZANNE TRUDEL ET AL.: "The inhibitory anti-FGFR3 antibody, PRO-OOl, is cytotoxic to t(4;14) multiple myeloma cells". BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US LNKD- DOI:10.1182/BL00D-2005-10-4179, vol. 107, no. 10, 15 May 2006 (2006-05-15), pages 4039-4046, XP007913063, ISSN: 0006-4971, cited in the application, the whole document *
WANG W. ET AL.: "200 POSTER Transcriptome analysis method for in vivo mechanism of action study: IMC-DI1 anti-FGFR3 +/- cisplatin in bladder cancer models". EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB LNKD-DOI:10.1016/S1359-6349 (08)72132-3, vol. 6, no. 12, 1 October 2008 (2008-10-01), page 63, XP025534262, ISSN: 1359-6349 [retrieved on 2008-10-01], cited in the application, Abstract 200 *

Also Published As

Publication number Publication date
ZA201101938B (en) 2012-08-29
WO2010048026A2 (en) 2010-04-29
TWI381848B (zh) 2013-01-11
CN103524620A (zh) 2014-01-22
CA2741127A1 (en) 2010-04-29
EA201170590A1 (ru) 2011-10-31
CN102186884B (zh) 2014-08-13
BRPI0919832A2 (pt) 2015-12-15
TW201026325A (en) 2010-07-16
US20120219563A1 (en) 2012-08-30
US8182815B2 (en) 2012-05-22
KR20110056554A (ko) 2011-05-30
NZ592369A (en) 2013-02-22
MX2011004317A (es) 2011-06-24
CN102186884A (zh) 2011-09-14
JP2012505912A (ja) 2012-03-08
US8043618B2 (en) 2011-10-25
CA2741127C (en) 2015-06-02
US20100098696A1 (en) 2010-04-22
IL211807A0 (en) 2011-06-30
US8404240B2 (en) 2013-03-26
KR101370798B1 (ko) 2014-03-14
JP5577345B2 (ja) 2014-08-20
US20120009200A1 (en) 2012-01-12
UA101681C2 (ru) 2013-04-25
WO2010048026A3 (en) 2010-07-15
AR073770A1 (es) 2010-12-01
AU2009307841B2 (en) 2013-09-12
AU2009307841A1 (en) 2010-04-29
BRPI0919832A8 (pt) 2019-01-08
EP2342232A2 (en) 2011-07-13

Similar Documents

Publication Publication Date Title
JP7301106B2 (ja) 線維芽増殖因子受容体２に対するモノクローナル抗体
US20250197526A1 (en) Trispecific binding proteins and methods of use
KR101370798B1 (ko) 섬유모세포 성장 인자 수용체-3 (ｆｇｆｒ-3) 억제제 및 치료 방법
JP2022502371A (ja) Ｄｌｌ３結合タンパク質および使用方法
KR20200042485A (ko) EGFR 및 cMET에 결합하는 항체
US20120121505A1 (en) Therapeutic compositions and methods
KR20220144841A (ko) Flt3 결합 단백질 및 사용 방법
JP6574257B2 (ja) 新規の抗Ｎｏｄａｌ抗体及びその使用方法
KR20140125351A (ko) 항-cd98 항체 및 이의 사용 방법
CN111848805B (zh) 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体
KR102887692B1 (ko) 항-bcam 항체 또는 그의 항원 결합 단편
CN109929036B (zh) 一种表位特异的抗体筛选方法及所筛选到的抗体
KR20230158058A (ko) 시알산-결합 ig-유사 렉틴 15에 특이적인 항체 및 이의 용도
CN112272564A (zh) 可标靶vegfr2与vegfr3的双功能抗体
EP3082858B1 (en) Adrenomedullin binder for use in therapy of cancer
TW202330026A (zh) 用於療法之抗btn3a活化抗體及il2促效劑之組合
KR20220048028A (ko) 항-cd19 항체 및 그의 용도
KR20240149030A (ko) 항-bcam 항체 및 항체-약물 접합체
CN118496364A (zh) uPARAP特异性结合蛋白及其制备方法和应用
NZ626513B2 (en) Anti-cd98 antibodies and methods of use thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU